Fatty acid binding protein 7 as a marker of glioma stem cells

Pathology International

Volumn 63, Issue 11, 2013, Pages 546-553

  Morihiro, Yusuke ^a   Yasumoto, Yuki ^a   Vaidyan, Linda Koshy ^a   Sadahiro, Hirokazu ^a   Uchida, Tomoyuki ^a   Inamura, Akinori ^a   Sharifi, Kazem ^a   Ideguchi, Makoto ^a   Nomura, Sadahiro ^a   Tokuda, Nobuko ^a,b   Kashiwabara, Shoji ^a   Ishii, Aya ^a   Ikeda, Eiji ^a   Owada, Yuji ^a   Suzuki, Michiyasu ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Research and Development Division   (Japan)

Author keywords

Differentiation; FABP7; Glioblastoma; Stem cells

Indexed keywords

FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 7; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTOMA; CANCER CELL; CANCER GRADING; CANCER STEM CELL; CELL DIFFERENTIATION; CELL NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOSOL; DOWN REGULATION; FEMALE; GLIOBLASTOMA; GLIOMA CELL; GLIOMA STEM CELL; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; WESTERN BLOTTING;

DIFFERENTIATION; FABP7; GLIOBLASTOMA; STEM CELLS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CARRIER PROTEINS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASTIC STEM CELLS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84888319273     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/pin.12109     Document Type: Article

References (36)

1. Stupp R, Mason WP, van den Bent MJ etal. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
2. Toda M, Iizuka Y, Yu W etal. Expression of the neural RNA-binding protein Musashi1 in human gliomas. Glia 2001; 34: 1-7.
3. Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, Steindler DA. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 2002; 39: 193-206.
4. Singh SK, Hawkins C, Clarke ID etal. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
5. Galli R, Binda E, Orfanelli U etal. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004; 64: 7011-7021.
6. Gursel DB, Shin BJ, Burkhardt JK, Kesavabhotla K, Schlaff CD, Boockvar JA. Glioblastoma stem-like cells-biology and therapeutic implications. Cancers (Basel) 2011; 3: 2655-2666.
7. Brescia P, Richichi C, Pelicci G. Current strategies for identification of glioma stem cells: Adequate or unsatisfactory? J Oncol 2012; 2012: 376894: 10.
8. Owada Y, Yoshimoto T, Kondo H. Spatio-temporally differential expression of genes for three members of fatty acid binding proteins in developing and mature rat brains. J Chem Neuroanat 1996; 12: 113-122.
9. Sharifi K, Morihiro Y, Maekawa M etal. FABP7 expression in normal and stab-injured brain cortex and its role in astrocyte proliferation. Histochem Cell Biol 2011; 136: 501-513.
10. Arai Y, Funatsu N, Numayama-Tsuruta K, Nomura T, Nakamura S, Osumi N. Role of Fabp7, a downstream gene of Pax6, in the maintenance of neuroepithelial cells during early embryonic development of the rat cortex. J Neurosci 2005; 25: 9752-9761.
11. Etcheverry A, Aubry M, de Tayrac M etal. DNA methylation in glioblastoma: Impact on gene expression and clinical outcome. BMC Genomics 2010; 11: 701.
12. Kaloshi G, Mokhtari K, Carpentier C etal. FABP7 expression in glioblastomas: Relation to prognosis, invasion and EGFR status. J Neurooncol 2007; 84: 245-248.
13. Liang Y, Bollen AW, Aldape KD, Gupta N. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma. BMC Cancer 2006; 6: 97.
14. De Rosa A, Pellegatta S, Rossi M etal. A radial glia gene marker, fatty acid binding protein 7 (FABP7), is involved in proliferation and invasion of glioblastoma cells. PLoS One 2012; 7: e52113.
15. Lee J, Kotliarova S, Kotliarov Y etal. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006; 9: 391-403.
16. Li A, Walling J, Kotliarov Y etal. Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol Cancer Res 2008; 6: 21-30.
17. Gilbert CA, Daou MC, Moser RP, Ross AH. Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence. Cancer Res 2010; 70: 6870-6879.
18. Beier D, Rohrl S, Pillai DR etal. Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 2008; 68: 5706-5715.
19. Bleau AM, Hambardzumyan D, Ozawa T etal. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009; 4: 226-235.
20. Mihaliak AM, Gilbert CA, Li L etal. Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres. Cancer Lett 2010; 296: 168-177.
21. Pollard SM, Yoshikawa K, Clarke ID etal. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 2009; 4: 568-580.
22. Sadahiro H, Yoshikawa K, Ideguchi M etal. Pathological features of highly invasive glioma stem cells in a mouse xenograft model. Brain Tumor Pathol 2013; DOI 10.1007/s10014-013-0149-x.
23. Miyake T, Ogawa E, Mikoshiba A etal. Epidermal-type FABP is a predictive marker of clinical response to systemic treatment and ultraviolet therapy in psoriatic skin lesions. J Dermatol Sci 2012; 68: 199-202.
24. Yanagita E, Kamoshida S, Imagawa N, Itoh T. Immunohistochemistry-based cell cycle detection (iCCD): A novel system to visualize cell kinetics on formalin-fixed paraffin-embedded tissues. Am J Surg Pathol 2012; 36: 769-773.
25. Annovazzi L, Mellai M, Caldera V, Valente G, Schiffer D. SOX2 expression and amplification in gliomas and glioma cell lines. Cancer Genomics Proteomics 2011; 8: 139-147.
26. Mita R, Coles JE, Glubrecht DD, Sung R, Sun X, Godbout R. B-FABP-expressing radial glial cells: The malignant glioma cell of origin? Neoplasia 2007; 9: 734-744.
27. Lathia JD, Hitomi M, Gallagher J etal. Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions. Cell Death Dis 2011; 2: e200.
28. Hanhoff T, Lucke C, Spener F. Insights into binding of fatty acids by fatty acid binding proteins. Mol Cell Biochem 2002; 239: 45-54.
29. Mita R, Beaulieu MJ, Field C, Godbout R. Brain fatty acid-binding protein and omega-3/omega-6 fatty acids: Mechanistic insight into malignant glioma cell migration. J Biol Chem 2010; 285: 37005-37015.
30. Inoue A, Takahashi H, Harada H etal. Cancer stem-like cells of glioblastoma characteristically express MMP-13 and display highly invasive activity. Int J Oncol 2010; 37: 1121-1131.
31. Yu SC, Bian XW. Enrichment of cancer stem cells based on heterogeneity of invasiveness. Stem Cell Rev 2009; 5: 66-71.
32. Brescia P, Ortensi B, Fornasari L, Levi D, Broggi G, Pelicci G. CD133 is essential for glioblastoma stem cell maintenance. Stem Cells 2013; 31: 857-869.
33. Huang Z, Cheng L, Guryanova OA, Wu Q, Bao S. Cancer stem cells in glioblastoma-molecular signaling and therapeutic targeting. Protein Cell 2010; 1: 638-655.
34. Gangemi RM, Griffero F, Marubbi D etal. SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 2009; 27: 40-48.
35. Christensen K, Schroder HD, Kristensen BW. CD133 identifies perivascular niches in grade II-IV astrocytomas. J Neurooncol 2008; 90: 157-170.
36. He H, Li MW, Niu CS. The pathological characteristics of glioma stem cell niches. J Clin Neurosci 2012; 19: 121-127.